Seoul National University Hospital 
Welcome,         Profile    Billing    Logout  
 3 Products   0 Diseases  3 Products   5 Trials   60 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
burfiralimab (hzVSF(IgG4)) / Immunemed
NCT05808335: A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)

Recruiting
2a
32
RoW
Standard of care
ImmuneMed, Inc.
Chronic Hepatitis B
03/24
12/24
Immunemed_COVID-07: ImmuneMed tests HzVSFv-13 on COVID-19 patients

Not yet recruiting
2
0
Korea
HzVSFv-13 - Immunemed, Seoul National University Hospital
Immunemed, Seoul National University Hospital
 
 
NCT04679350: Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

Terminated
2
1
RoW
hzVSF-v13, a humanized monoclonal antibody (mAb), Placebo (Normal saline solution), 0.9% Normal saline
ImmuneMed, Inc.
COVID-19
11/22
12/22
NCT06306339: A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

Not yet recruiting
2
60
Europe
Burfiralimab, hzVSF-v13, SOC (Standard of care), bDMARD or csDMARD, Placebo, The placebo for Burfiralimab (hzVSF-v13)
ImmuneMed, Inc.
Moderate to Severe Rheumatoid Arthritis
05/25
07/25
NCT04817202: Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)

Completed
1
72
RoW
hzVSF-v13 (intravenous, single dose), a humanized monoclonal antibody (mAb), hzVSF-v13 (subcutaneous, single dose), hzVSF-v13 (intravenous, multiple dose), Placebo (intravenous, single dose), 0.9% Normal saline, Placebo (subcutaneous, single dose), Placebo (intravenous, multiple dose)
ImmuneMed, Inc.
Healthy Volunteers
01/22
07/22
SNUH-CD19-CAR-T / Seoul National University Hospital
NCT06247501: Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation

Recruiting
2
50
RoW
SNUH-CD19-CAR-T
Seoul National University Hospital
Very High Risk Acute Lymphoblastic Leukemia, CD19 CAR-T Therapy
12/28
12/29
NCT05210907: Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Recruiting
1
5
RoW
SNUH-CD19-CAR-T
Seoul National University Hospital
B-cell Acute Lymphoblastic Leukemia
09/25
08/26
RS22802 / Seoul National University Hospital
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
burfiralimab (hzVSF(IgG4)) / Immunemed
NCT05808335: A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)

Recruiting
2a
32
RoW
Standard of care
ImmuneMed, Inc.
Chronic Hepatitis B
03/24
12/24
Immunemed_COVID-07: ImmuneMed tests HzVSFv-13 on COVID-19 patients

Not yet recruiting
2
0
Korea
HzVSFv-13 - Immunemed, Seoul National University Hospital
Immunemed, Seoul National University Hospital
 
 
NCT04679350: Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

Terminated
2
1
RoW
hzVSF-v13, a humanized monoclonal antibody (mAb), Placebo (Normal saline solution), 0.9% Normal saline
ImmuneMed, Inc.
COVID-19
11/22
12/22
NCT06306339: A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

Not yet recruiting
2
60
Europe
Burfiralimab, hzVSF-v13, SOC (Standard of care), bDMARD or csDMARD, Placebo, The placebo for Burfiralimab (hzVSF-v13)
ImmuneMed, Inc.
Moderate to Severe Rheumatoid Arthritis
05/25
07/25
NCT04817202: Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)

Completed
1
72
RoW
hzVSF-v13 (intravenous, single dose), a humanized monoclonal antibody (mAb), hzVSF-v13 (subcutaneous, single dose), hzVSF-v13 (intravenous, multiple dose), Placebo (intravenous, single dose), 0.9% Normal saline, Placebo (subcutaneous, single dose), Placebo (intravenous, multiple dose)
ImmuneMed, Inc.
Healthy Volunteers
01/22
07/22
SNUH-CD19-CAR-T / Seoul National University Hospital
NCT06247501: Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation

Recruiting
2
50
RoW
SNUH-CD19-CAR-T
Seoul National University Hospital
Very High Risk Acute Lymphoblastic Leukemia, CD19 CAR-T Therapy
12/28
12/29
NCT05210907: Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Recruiting
1
5
RoW
SNUH-CD19-CAR-T
Seoul National University Hospital
B-cell Acute Lymphoblastic Leukemia
09/25
08/26
RS22802 / Seoul National University Hospital
No trials found

Download Options